[logo] HealthTree Foundation
search more_vert
close
person Sign In / Create Account
arrow_back

Go back to trials list

Epigenetic Modification for Relapse Prevention: a Dose-finding Study of Vorinostat Used in Combination With Low-dose Azacitidine in Children Undergoing Allogeneic Hematopoietic Cell Transplantation for Myeloid Malignancies


Description

The objective of this study is to evaluate the maximum tolerated (MTD) of vorinostat used in combination with low-dose azacitidine after allogeneic hematopoietic cell transplantation (alloHCT) for prevention of relapse of childhood myeloid malignancies.Children and adolescents ages 1 to 21 years of age who are undergoing allogeneic hematopoietic cell transplantation for a myeloid malignancy (AML, MDS, JMML, MPAL) will be eligible. There are no restrictions on donor type, conditioning, stem cell source, of GVHD prophylaxis approach. All participants will be treated on a single arm, and will initially receive 2 cycles of standard post-transplant azacitidine at a dose of 32mg/m2/dose IV/subcutnaeous for 5 days, in 28 day cycles. This is considered standard of care. After tolerance of 2 cycles of azacitidine has been established, patients will be assigned to receive vorinostat orally at different dose levels, depending on the stage of the study. The dose level assignments will be conduct

Trial Eligibility

Inclusion Criteria: 1. Patient is 1 year to 21 years of age. 2. Patient has a diagnosis of AML, MDS, MDS/AML, MPAL, or JMML. Note: patients are allowed to have received a HMA or HDACi prior to undergoing alloHCT. 3. Patient has undergone allogeneic hematopoietic cell transplantation (no restrictions on conditioning regimen, donor or stem cell source, or GVHD prophylaxis regimen). 4. Patient and/or parent(s) or legal guardian(s) are capable of understanding the study, including potential benefits and risks, and sign written informed consent. Age-appropriate assent will be obtained. 5. Female patient of childbearing potential has a negative screening pregnancy test (urine or serum, as per local institutional standard). 6. Female patient with infant(s) agrees not to breastfeed her infant(s) while on study. 7. Patient of child-bearing potential (male and female) agrees to use effective method of contraception during the study. Exclusion Criteria: 1. Patient is enrolled on a clinical trial with investigational post-transplant medications. Note: trials involving defibrotide, post-transplant cyclophosphamide, and Lactobacillus plantarum are permitted. Other trials involving investigational medications that aren't leukemia or GVHD-directed may also be permitted after consultation with the overall PI. 2. Patient has a planned administration of non-protocol chemotherapy, radiation therapy, donor leukocyte infusion, or immunotherapy during the planned study period. 3. Patient has a known allergy to azacitidine or vorinostat. 4. Patient has chronic myelogenous leukemia. 5. Concomitant use of coumarin-derived anticoagulants or valproic acid. -

Study Info

Organization

Johns Hopkins All Children's Hospital


Primary Outcome

Maximum tolerated dose (MTD)


Outcome Timeframe 4 months

NCTID NCT03843528

Phases PHASE1

Primary Purpose TREATMENT

Start Date 2019-05-01

Completion Date 2025-07-30

Enrollment Target 15

Interventions

DRUG Vorinostat

DRUG Azacitidine Injection

Locations Recruiting

Johns Hopkins All Children's Hospital

United States, Florida, Saint Petersburg


Interested in joining this trial?

Our dedicated patient navigators are here to guide you through the validation and enrollment process with ease.

newsletter icon

Get the latest thought leadership on your Juvenile Myelomonocytic Leukemia delivered straight to your inbox

Subscribe to the weekly newsletter for news, stories, clinical trial updates, and helpful resources and events with cancer experts.